Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 10/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.32 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1301528 | 0.91 | METTL3 (0.49) | METTL3PDCD1CD274GRIN1GRIN2B | |
| SCHEMBL1301532 | 0.91 | METTL3 (0.49) | METTL3PDCD1CD274GRIN1GRIN2B | |
| SCHEMBL12107664 | 0.88 | METTL3 (0.42) | METTL3 | |
| SCHEMBL12107653 | 0.88 | METTL3 (0.46) | METTL3GRM2 | |
| SCHEMBL12107671 | 0.87 | METTL3 (0.41) | METTL3 | |
| SCHEMBL12107665 | 0.87 | METTL3 (0.41) | METTL3 | |
| SCHEMBL12107672 | 0.86 | METTL3 (0.42) | METTL3 | |
| SCHEMBL12107714 | 0.82 | METTL3 (0.40) | METTL3 | |
| SCHEMBL12413342 | 0.82 | METTL3 (0.42) | METTL3 | |
| SCHEMBL13771406 | 0.81 | METTL3 (0.40) | METTL3GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885PDCD1 4195/4885CD274 4553/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885PDCD1 4195/4885CD274 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.